• 1
    Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 9017.
  • 2
    Schulman S, Rhedin A-S, Lindmarker P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 16615.
  • 3
    Schulman S. Quality of oral anticoagulant control and treatment in Sweden: Duration Anticoagulation (DURAC) Trial Study Group. J Intern Med 1994; 236: 14352.
  • 4
    Schulman S, Granqvist S, Holmström M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 3938.
  • 5
    Hutten BA & Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (Cochrane Review). In: The Cochrane Library, Issue 4. 2000; Oxford: Update Software.
  • 6
    Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000; 160: 34316.
  • 7
    Schulman S & Büller H. Optimization of treatment for venous thromboembolism and prevention of recurrences. Haemostasis 1999; 29 (Suppl. 1): 7980.
  • 8
    Zacharski LR & Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 1023.
  • 9
    Schulman S & Lindmarker P, and the DURAC Trial Study Group. Incidence of cancer after secondary prophylaxis against venous thromboembolism with warfarin. N Engl J Med 2000; 342: 19538.